Filament Health, based in Vancouver, is a leader in natural medicine development and is pioneering a groundbreaking medical grade ayahuasca pill.
This pill could potentially help people access an authentic experience without disrupting their daily lives or taking a trip to South America. Filament Health is on the verge of receiving FDA approval to begin a groundbreaking Phase 1 clinical trial of the pill. The history of using ayahuasca goes back centuries. It was used in Central and South America for its powerful, healing and visionary effects. The psychedelic experience of the drug has grown in popularity, especially among the rich and famous.
With a large body of research demonstrating its potential therapeutic effects, the compound has been identified as a potential drug to treat a range of mental and physical illnesses such as depression, suicidality, anxiety, trauma, grief, addiction and substance use disorders to even neurodegenerative diseases. to treat.
The benefits of an Ayahuasca pill
Why bother making a pill when we can already brew and drink traditional hallucinogenic teas at retreats in Brazil or Peru and visit ayahuasca churches in Canada and the US? The answer lies in accessibility and consistency – two critical elements essential to exploring this powerful drug.
One of the biggest problems with administering ayahuasca in a traditional setting is that there is extreme variability in how much people get. This can lead to drastically different experiences for different people, within the same ceremony, making it difficult to measure the effects and benefits of ayahuasca use.
A consistent experience
By creating an ayahuasca pill and standardizing dosage, researchers hope to create a more consistent experience with predictable effects. This allows for a more accurate study of the therapeutic potential.
Another benefit of making an ayahuasca pill would be that it could make the treatment more accessible to people who cannot travel to South America for traditional ceremonies or have access to professionals.
Source: psychedelic spotlight (EN)
